Vertex Pharmaceuticals (VRTX) has been one of the most searched-for stocks on Zacks.com lately. So, you might want to look at ...

Wondering whether Vertex Pharmaceuticals is still worth buying at around $452 a share, or if the big gains are already behind ...

Vertex Pharmaceuticals (VRTX) just checked several big boxes at once, with upbeat pediatric data for CASGEVY, fresh momentum in its kidney disease program, and a wave of investor interest following ...

Vertex Pharmaceuticals is acquiring Alpine Immune Sciences for $4.9 billion, gaining access to povetacicept, a potential treatment for IgA nephropathy and up to seven additional indications.

Vertex Pharmaceuticals Incorporated remains a buy despite recent share price weakness, supported by its dominant cystic fibrosis franchise and robust late-stage pipeline. Alyftrek's launch extends ...

So far, the company's commercialized drugs have delivered billions of dollars in revenue. For example, in the latest quarter, Vertex's revenue soared 11% to more than $3 billion -- that's with net ...

Vertex Pharmaceuticals (VRTX) has recently been on Zacks.com's list of the most searched stocks. Therefore, you might want to consider some of the key factors that could influence the stock's ...

Vertex Pharmaceuticals (NDAQ: VRTX) stands today as a top 20 pharma company with over a $100 billion market cap. But this biotech beacon has ridden a bumpy path to its current perch and, along the way ...

Just last week, I wrote why you'd be smart to buy Vertex Pharmaceuticals (VRTX-0.63%) stock. At that time, Vertex was up around 70% for the year. My argument then was that the stock was still ...

Vertex AI is a comprehensive machine learning platform by Google Cloud, provides an all-inclusive suite of tools and resources for the creation, deployment, and customization of machine learning ...

Vertex Pharmaceuticals (NASDAQ: VRTX) has been a big disappointment for investors in 2021. While the S&P 500 index soared nearly 30%, Vertex's shares are down 5%. Investors are much more focused on ...